scholarly journals The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?

2021 ◽  
Vol Volume 13 ◽  
pp. 8457-8471
Author(s):  
Michael Patrick Lux ◽  
Oriana Ciani ◽  
William CN Dunlop ◽  
Andrea Ferris ◽  
Michael Friedlander
Keyword(s):  
Decision Making ◽  
Overall Survival ◽  
Reimbursement Decision

scholarly journals Drug pricing and reimbursement decision making systems in Mongolia

2017 ◽  
Vol 10 (1) ◽  
Author(s):  
Gereltuya Dorj ◽  
Bruce Sunderland ◽  
Tsetsegmaa Sanjjav ◽  
Gantuya Dorj ◽  
Byambatsogt Gendenragchaa
Keyword(s):  
Decision Making ◽  
Reimbursement Decision ◽  
Drug Pricing ◽  
Pricing And Reimbursement

scholarly journals How Should the Value Attributes of Novel Antibiotics Be Considered in Reimbursement Decision Making?

2019 ◽  
Vol 4 (2) ◽  
pp. 238146831989223
Author(s):  
Alec Morton ◽  
Abigail Colson ◽  
Axel Leporowski ◽  
Anna Trett ◽  
Taimur Bhatti ◽  
...  
Keyword(s):  
Decision Making ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Bacterial Infections ◽  
Health Care Systems ◽  
Full Range ◽  
Health Technology ◽  
Optimal Level ◽  
Reimbursement Decision ◽  
Novel Antibiotics

Antibiotics have revolutionized the treatment of bacterial infections. However, it is widely held that there is underinvestment in antibiotics research and development relative to the socially optimal level for a number of reasons. In this article, we discuss whether existing health technology assessment procedures recognize the full economic and societal value of new antibiotics to patients and society when making reimbursement decisions. We present three recommendations for modelling the unique attributes of value that are specific to novel antibiotics. We find, based on a review of the literature, that some of the value elements proposed by our framework have previously been discussed qualitatively by health technology assessment bodies when evaluating antibiotics, but are not yet formally captured via modelling. We present a worked example to show how it may be possible to capture these dimensions of value in a more quantitative manner. We conclude by answering the question of the title as follows: the unique attributes of novel antibiotics should be considered in reimbursement decision making, in a way that captures the full range of benefits these important technologies bring to patients, health care systems, and society.

scholarly journals Association of Surgical Delay and Overall Survival in Patients With T2 Renal Masses: Implications for Critical Clinical Decision-making During the COVID-19 Pandemic

Urology ◽  
2021 ◽  
Vol 147 ◽  
pp. 50-56
Author(s):  
Kevin B. Ginsburg ◽  
Gannon L. Curtis ◽  
Devin N. Patel ◽  
Wen Min Chen ◽  
Marshall C. Strother ◽  
...  
Keyword(s):  
Decision Making ◽  
Overall Survival ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Renal Masses ◽  
Surgical Delay
Sign in / Sign up

Export Citation Format

Share Document